Financial PerformanceThe company achieved a 9% revenue beat with 66% year-over-year growth in Q3, highlighting its strong performance.
Product DemandPRCT's new robot Hydros represented 80% of the US systems sold in Q3, indicating strong future demand.
Regulatory ApprovalPRCT received FDA approval to initiate a pivotal study of Aquablation in prostate cancer, representing an incremental positive for the stock.